Showing results (751-760 of 2,753) with videos related to

Sort By:
Pageof 276
Neoplasia (New York, N.Y.)|January 20, 2011
On-target inhibition of tumor fermentative glycolysis as visualized by hyperpolarized pyruvatePankaj Seth, Aaron Grant, Jian Tang, et al.
Neoplasia (New York, N.Y.)|August 7, 2010
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanomaWilliam D Tap, Ke-Wei Gong, Judy Dering, et al.
Neoplasia (New York, N.Y.)|July 24, 2010
Differential influence of anticancer treatments and angiogenesis on the seric titer of autoantibody used as tumor and metastasis biomarkerFlorence Defresne, Caroline Bouzin, Céline Guilbaud, et al.
Neoplasia (New York, N.Y.)|June 22, 2010
Invasive glioblastoma cells acquire stemness and increased Akt activationJennifer R Molina, Yuho Hayashi, Clifton Stephens, et al.
Neoplasia (New York, N.Y.)|May 11, 2010
The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivoMi-Ae Lyu, Deepak Rai, Kwang Seok Ahn, et al.
Neoplasia (New York, N.Y.)|May 11, 2010
Comparison of tumor and microenvironment secretomes in plasma and in platelets during prostate cancer growth in a xenograft modelBethany A Kerr, Ranko Miocinovic, Armine K Smith, et al.
Neoplasia (New York, N.Y.)|May 11, 2010
Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signalingManjinder Kaur, Balaiya Velmurugan, Alpna Tyagi, et al.
Neoplasia (New York, N.Y.)|May 11, 2010
Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanismsStacey L Hembruff, Iman Jokar, Li Yang, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Optical molecular imaging of epidermal growth factor receptor expression to improve detection of oral neoplasiaNitin Nitin, Kelsey J Rosbach, Adel El-Naggar, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancerYa-Ting Yang, Curt Balch, Samuel K Kulp, et al.
Pageof 276